But the new findings suggest that people with desmoplastic melanoma could receive pembrolizumab alone and be spared the unnecessary side effects of additional therapies, according to the researchers who conducted the phase II clinical trial.
Two combinations of immunotherapy drugs have been approved for melanoma. People with desmoplastic melanoma, a rare form of skin cancer, are likely to benefit from treatment with a single immunotherapy drug, pembrolizumab (Keytruda), new results from a small clinical trial suggest.
0 kommentar(er)
